secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001628280-21-015239
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q2 net loss $43.7M; NEXLETOL/NEXLIZET net product revenue $10.6M up 67% QoQ
--------------------------------------------------------------------------------

- U.S. net product revenue $10.6M, up 67% sequentially; prescriptions grew 28% during quarter.
- Net loss $43.7M ($1.67/share) vs net income $124.6M in Q2 2020 on decline in milestone revenue.
- Total revenue $40.7M (vs $212.2M Q2 2020); collaboration revenue fell due to lack of milestone payments.
- Cash $219.2M at June 30; 2021 full-year operating expense guidance $320M-$340M.
- Director Daniel Janney resigned effective July 28; Nicole Vitullo appointed to Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/0001628280-21-015239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/espr-20210728.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-015239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer